Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Director/PDMR Shareholding

12th Dec 2011 16:20

Share Dealing by Person Discharging Managerial Responsibility

December 12, 2011 - Shire plc , the global specialty biopharmaceutical company (the "Company") announces that it was notified on December 9, 2011 of the following dealings in Shire plc ordinary shares ("Shares).

Exercise of Stock Appreciation Rights ("SAR Awards") and Options

On December 9, 2011, Tatjana May exercised a SAR Award granted under the ShirePortfolio Share Plan. In addition, Ms May exercised an option granted under the2000 Executive Share Option Scheme. The resulting Shares were sold on theLondon Stock Exchange. Number of Exercise Number of Shares Average sale price price Shares released and exercised sold SAR Award 32,000 £9.97 16,965 £21.15678 Option 70,000 £5.585 51,576 £21.13278

Following the above transactions, Ms May holds 86,126 Shares, options over 81,108 Shares and awards of Stock Appreciation Rights, Performance Shares and Restricted Shares over 210,787 Shares.

This notification relates to disclosures made in accordance with 3.1.4(R)(1)(a) of the Disclosure and Transparency Rules.

Tony GuthrieDeputy Company Secretary

For further information please contact:

Investor Eric Rojas [email protected] +1 781 482 0999 Relations Sarah Elton-Farr [email protected] +44 1256 894157

Notes to editors

SHIRE PLC

Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit hyperactivity disorder, human genetic therapies, gastrointestinal diseases and regenerative medicine as well as opportunities in other therapeutic areas to the extent they arise through acquisitions. Shire's in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights. Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.

For further information on Shire, please visit the Company's website: www.shire.com.

Registered in Jersey, No. 99854, 22 Grenville Street, St Helier, Jersey JE4 8PXPress Release

www.shire.com

XLON

Related Shares:

Shire
FTSE 100 Latest
Value9,068.58
Change-64.23